Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 14Terminated 5Recruiting 5Completed 4Withdrawn 2Suspended 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Specimen Handling 76Cisplatin 64Drug Therapy 63Carboplatin 63Bevacizumab 63Magnetic Resonance Spectroscopy 59Radiotherapy 57Gemcitabine 54Cyclophosphamide 54pembrolizumab 52Oxaliplatin 49Capecitabine 49toripalimab 44Paclitaxel 40tislelizumab 39Standard of Care 39fludarabine 36Injections 34Fluorouracil 34Biopsy 34venetoclax 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 28Nivolumab 28Surgical Procedures, Operative 27Irinotecan 27Docetaxel 27Leucovorin 26Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × tazemetostat × 1 year × Clear all
NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Ruijin Hospital

Phase 1/2 Not yet recruiting
48 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡